Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer Now With Survival Benefit, CDK4/6 Inhibitors in Breast Cancer

New data for overall survival now establish adding the CDK4/6 inhibitors abemaciclib and ribociclib to endocrine therapy for frontline use in HR+/HER2- advanced breast cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news